Impact & governance
Measuring what matters, before claiming it.
This page sets out how CHP intends to define impact and structure oversight. We publish definitions rather than figures, because no verified measurements exist yet.
How we would measure impact
Four definitions.
Each category describes what would be counted and how. Values will only appear once they are verified.
- Patients reached
- DefinitionUnique patients served through deployed innovations, with appropriate aggregation and privacy safeguards.
- Hospitals adopting
- DefinitionFacilities using a validated technology in routine clinical care.
- Cost per outcome
- DefinitionThe economic efficiency of an intervention against an appropriate comparator.
- Published evidence
- DefinitionPeer-reviewed work and relevant regulator-recognised evidence generated through evaluation and deployment.
Proposed governance model
Oversight designed into the process.
The following structures are proposed as CHP is established. They are not yet constituted, and naming them is not a claim of regulatory status or permissions.
Investment committee
A proposed committee to review opportunities and stage-gate decisions.
Clinical advisory input
A proposed panel of clinical and operational reviewers for evaluation and validation.
Ethics and data protection
Evaluation work carried out under institutional approval and applicable data-protection requirements.
Conflicts and independence
Proposed policies for declaring interests and separating clinical review from commercial decisions.
Responsible practice
What we will not do.
We will not present intended activity as completed activity, publish outcome figures that have not been verified, or describe a technology as validated beyond the evidence available for its intended use.
We will not use patient information outside properly approved arrangements, and we will not name partners, companies or programmes without their agreement.